This case-controlled study asked whether injecting bone marrow-derived mesenchymal stem cells (MSCs) at the tendon-bone interface during arthroscopic rotator cuff repair improves healing and prevents re-tears. 45 MSC-treated patients were matched to 45 controls who underwent identical single-row repair without augmentation, with imaging follow-up out to ten years.
30,000 MSCs → ≥2 cm² footprint healed by 3 months
Re-tear rates after arthroscopic rotator cuff repair consistently exceed 25% in the literature, and revision surgery is technically harder with worse outcomes. The question of whether the biology of healing — not just the mechanics of fixation. Could be improved had no strong human evidence with long-term follow-up before this paper.
This study is why biologic augmentation of rotator cuff repair is a legitimate strategy worth knowing. When MSC dose exceeded 30,000 cells, every patient healed by six months. When dose fell below this threshold, failures clustered in exactly the same window (3-6 months postop) as the unaugmented controls.
The practical implication: the iliac crest harvest technique matters. Aspirating in small 4 mL fractions across multiple perforations spaced 2 cm apart is specifically designed to minimize peripheral blood dilution and maximize progenitor cell yield. Technique details that directly determine whether the cell dose crosses the therapeutic threshold.
The ten-year data also show that failed repairs drive Goutallier fatty infiltration progression, reinforcing that durability of repair is not just a structural endpoint but a long-term muscle biology endpoint.
This case-controlled study asked whether injecting bone marrow-derived mesenchymal stem cells (MSCs) at the tendon-bone interface during arthroscopic rotator cuff repair improves healing and prevents re-tears. 45 MSC-treated patients were matched to 45 controls who underwent identical single-row repair without augmentation, with imaging follow-up out to ten years.
30,000 MSCs → ≥2 cm² footprint healed by 3 months
Re-tear rates after arthroscopic rotator cuff repair consistently exceed 25% in the literature, and revision surgery is technically harder with worse outcomes. The question of whether the biology of healing — not just the mechanics of fixation. Could be improved had no strong human evidence with long-term follow-up before this paper.
This study is why biologic augmentation of rotator cuff repair is a legitimate strategy worth knowing. When MSC dose exceeded 30,000 cells, every patient healed by six months. When dose fell below this threshold, failures clustered in exactly the same window (3-6 months postop) as the unaugmented controls.
The practical implication: the iliac crest harvest technique matters. Aspirating in small 4 mL fractions across multiple perforations spaced 2 cm apart is specifically designed to minimize peripheral blood dilution and maximize progenitor cell yield. Technique details that directly determine whether the cell dose crosses the therapeutic threshold.
The ten-year data also show that failed repairs drive Goutallier fatty infiltration progression, reinforcing that durability of repair is not just a structural endpoint but a long-term muscle biology endpoint.